BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.310
+0.060 (4.80%)
At close: Jun 26, 2026, 4:00 PM EDT
1.300
-0.010 (-0.76%)
After-hours: Jun 26, 2026, 7:53 PM EDT

BioXcel Therapeutics Stock Forecast

Stock Price Forecast

The 3 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 7.67, with a low estimate of 1.00 and a high estimate of 17. The average target predicts an increase of 485.50% from the current stock price of 1.31.

Analyst Consensus: Buy
Target Low Average Median High
Price $1.00 $7.67 $5.00 $17
Change -23.66% +485.50% +281.68% +1197.7%
* Price targets were last updated on Apr 10, 2026.

Analyst Ratings

The average analyst rating for BioXcel Therapeutics stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Dec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy 333333
Buy 000000
Hold 000000
Sell 111111
Strong Sell 000000
Total 444444

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$5
Buy Reiterates $5 +281.68% Apr 10, 2026
Bank of America Securities
Bank of America Securities
Sell
Reiterates
$1
Sell Reiterates $1 -23.66% Mar 27, 2026
Rodman & Renshaw
Rodman & Renshaw
Buy
Initiates
$17
Buy Initiates $17 +1,197.71% Mar 17, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
769.92K
from 642.00K
Increased by 19.93%
Revenue Next Year
18.93M
from 769.92K
Increased by 2,359.15%
EPS This Year
-2.62
from -5.71
EPS Next Year
-1.54
from -2.62
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
-375.00K1.38M2.27M642.00K769.92K18.93M
Revenue Growth
--268.00%64.20%-71.67%19.93%2,359.15%
EPS
-64.87-94.67-98.33-23.51-5.73-2.62-1.54
EPS Growth
-------
Forward PE
-------
No. Analysts -----13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202620272028
High 769,920 30.7M
Avg 769,920 18.9M
Low 769,920 5.3M

Revenue Growth

Revenue Growth 202620272028
High
19.9%
3,887.4%
Avg
19.9%
2,359.1%
Low
19.9%
591.6%

EPS Forecast

EPS 202620272028
High - -
Avg -2.62 -1.54
Low - -

EPS Growth

EPS Growth 202620272028
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.